Dr. Lal PathLabs strengthens its genomics capabilities with Illumina’s NovaSeq X Series

New Delhi, June 25, 2025: Dr. Lal PathLabs Limited (“DLPL”), one of India’s most trusted diagnostic chains,
has expanded its genomics capabilities by adding Illumina’s NovaSeq™ X Series to its dedicated genomics
division, Genevolve. With the integration of Illumina’s latest technology, DLPL can now deliver faster and
more accurate genomic research insights.

The NovaSeq™ X system features Illumina’s cutting-edge XLEAP-SBS™ chemistry, offering unmatched
throughput, accuracy, and sustainability. The NovaSeq X Plus can generate more than 20,000 whole
genomes per year, more than double the throughput of Illumina’s previous sequencers. Its unprecedented
speed, scale, and accuracy push the limits of what’s possible in genetic sequencing. And its powerful
technology allows users to unlock previously unimaginable discoveries and advancements.

“With the addition of Illumina’s NovaSeq X Series, we are taking another step forward in driving innovation
and scientific excellence,” said Mr. Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. “This investment
allows us to broaden our capabilities and contribute meaningfully to India’s evolving genomics landscape.”
Launched in 2019, Genevolve has swiftly emerged as a DNA-based center of excellence. The addition of
Illumina products further strengthens Genevolve’s position as a pioneer in next-generation sequencing
(“NGS”), enabling DLPL to deliver actionable, AI-powered insights with greater speed and sensitivity.

“At Genevolve, our mission has always been to push the boundaries of genomic innovation. Bringing the
NovaSeq X Series into our portfolio is a testament to that commitment, combining the power of nextgeneration sequencing and AI to enable faster, more precise, and meaningful insights for better
outcomes,” said Dr. Vandana Lal, Executive Director, Dr. Lal PathLabs Limited.

“As Illumina continues to grow in India, we are committed to democratizing access to sequencing
technologies”. Said Gregory Essert, General Manager, Emerging Markets, Illumina. NovaSeq X Series
represents our leadership in next-generation sequencing, and we are pleased to see it being adopted by
institutions like Dr. Lal PathLabs, which are at the forefront of driving scientific discovery and access to
genomic insights in India. We hope this empowers them to reach their goals more quickly.”

“Our longstanding vision has been to accelerate India’s adoption of next-generation sequencing
technologies. We are proud to support Dr. Lal PathLabs in integrating the NovaSeq X platform into their
genomics ecosystem, driving transformative research and innovation,” said Praveen Gupta, Managing
Director, Premas Life Sciences.

Dr. Lal PathLabs Limited and Illumina aim to engage closely with India’s medical and scientific communities
to build awareness and capacity for genomics-based decision-making.